Skip to main content

CRIBADO POBLACIONAL DE FIBROSIS HEPATICA CON ELASTOGRAFIA TRANSITORIA EN PERSONAS CON FACTORES DE RIESGO DE ENFERMEDAD HEPATICA E INDICE DE GRASA HEPATICA ELEVADO. ESTUDIO DE VALIDACION.

PI18/01330

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life

  • Carol, Marta
  • Pérez-Guasch, Martina
  • Solà, Elsa|||0000-0001-6897-2760
  • Cervera, Marta
  • Martínez, Sara
  • Juanola, Adrià|||0000-0003-4832-5130
  • Ma, Ann T.|||0000-0002-9059-111X
  • Avitabile, Emma
  • Napoleone, Laura
  • Pose, Elisa|||0000-0002-0224-7686
  • Graupera, Isabel|||0000-0001-9170-9784
  • Honrubia Pérez, María|||0000-0002-5605-2825
  • Korenjak, Marko|||0000-0003-4024-677X
  • Torres, Ferran|||0000-0002-7355-7913
  • Ginès, Pere|||0000-0003-4657-4504
  • Fabrellas, Núria|||0000-0001-6720-0291
Stigmatization is a well-documented problem of some diseases. Perceived stigma is common in alcohol-related liver disease and hepatitis C, but little information exists on stigma in patients with non-alcoholic fatty liver disease (NAFLD). Aim of the study was to investigate frequency and characteristics of perceived stigma among patients with NAFLD. One-hundred and ninety-seven patients seen at the liver clinic were included: a study group of 144 patients with NAFLD, 50 with cirrhosis (34 compensated, 16 decompensated), and a control group of 53 patients with alcohol-related cirrhosis. Demographic, clinical, and laboratory data were collected. Quality-of-life was assessed by chronic liver disease questionnaire (CLDQ). Perceived stigma was assessed using a specific questionnaire for patients with liver diseases categorized in 4 domains: stereotypes, discrimination, shame, and social isolation. Perceived stigma was common in patients with NAFLD (99 patients, 69%) and affected all 4 domains assessed. The frequency was slightly higher, yet not significant, in patients with NAFLD cirrhosis vs those without (72% vs 67%, respectively; p = 0.576). In patients without cirrhosis perceived stigma was unrelated to stage of disease, since frequency was similar in patients with no or mild fibrosis compared to those with moderate/severe fibrosis (66% vs 68%, respectively). There were no differences in perceived stigma between patients with compensated cirrhosis and these with decompensated cirrhosis. Among patients with cirrhosis, stigmatization was more common in alcohol-related vs NAFLD-cirrhosis, yet differences were only significant in two domains. In patients with NAFLD, perceived stigma correlated with poor quality-of-life, but not with demographic or clinical variables. Perceived stigmatization is common among patients with NAFLD independently of disease stage, is associated with impaired quality-of-life, and may be responsible for stereotypes, discrimination, shame, and social isolation, which may affect human and social rights of affected patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

LiverScreen project, study protocol for screening for liver fibrosis in the general population in European countries

  • Graupera, Isabel|||0000-0001-9170-9784
  • Thiele, Maja
  • Ma, Ann T.|||0000-0002-9059-111X
  • Serra-Burriel, Miquel
  • Pich, Judit
  • Fabrellas, Núria|||0000-0001-6720-0291
  • Caballería, Llorenç|||0000-0002-7990-0719
  • de Knegt, Robert J.
  • Grgurevic, Ivica
  • Reichert, Mathias
  • Roulot, Dominique
  • Schattenberg, Jörn M.
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Angeli, Paolo|||0000-0002-1913-0716
  • Tsochatzis, Emmanuel A.
  • Guha, Indra Neil
  • Garcia-Retortillo, M.|||0000-0001-6783-7604
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Hernández, Rosario
  • Hoyo, Jordi
  • Fuentes, Matilde
  • Madir, Anita
  • Juanola, Adrià|||0000-0003-4832-5130
  • Soria, Anna|||0000-0001-5671-8343
  • Juan, Marta
  • Carol, Marta
  • Díaz, Alba|||0000-0002-0456-7085
  • Detlefsen, Sönke
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Fournier, Céline
  • Llorca, Anne
  • Newsome, Phillip N.
  • Manns, Michael|||0000-0002-4485-8856
  • de Koning, Harry J.
  • Serra-Burriel, Feliu
  • Cucchietti, Fernando|||0000-0002-9027-1263
  • Arslanow, Anita
  • Korenjak, Marko|||0000-0003-4024-677X
  • van Kleef, Laurens
  • Falcó, Josep Lluis
  • Kamath, P.S.|||0000-0002-7888-1165
  • Karlsen, Tom H.
  • Castera, Laurent
  • Lammert, Frank
  • Krag, Aleksander|||0000-0002-9598-4932
  • Ginès, Pere|||0000-0003-4657-4504
The development of liver cirrhosis is usually an asymptomatic process until late stages when complications occur. The potential reversibility of the disease is dependent on early diagnosis of liver fibrosis and timely targeted treatment. Recently, the use of non-invasive tools has been suggested for screening of liver fibrosis, especially in subjects with risk factors for chronic liver disease. Nevertheless, large population-based studies with cost-effectiveness analyses are still lacking to support the widespread use of such tools. The aim of this study is to investigate whether non-invasive liver stiffness measurement in the general population is useful to identify subjects with asymptomatic, advanced chronic liver disease. This study aims to include 30,000 subjects from eight European countries. Subjects from the general population aged ≥ 40 years without known liver disease will be invited to participate in the study either through phone calls/letters or through their primary care center. In the first study visit, subjects will undergo bloodwork as well as hepatic fat quantification and liver stiffness measurement (LSM) by vibration-controlled transient elastography. If LSM is ≥ 8 kPa and/or if ALT levels are ≥1.5 x upper limit of normal, subjects will be referred to hospital for further evaluation and consideration of liver biopsy. The primary outcome is the percentage of subjects with LSM ≥ 8kPa. In addition, a health economic evaluation will be performed to assess the cost-effectiveness and budget impact of such an intervention. The project is funded by the European Commission H2020 program. This study comes at an especially important time, as the burden of chronic liver diseases is expected to increase in the coming years. There is consequently an urgent need to change our current approach, from diagnosing the disease late when the impact of interventions may be limited to diagnosing the disease earlier, when the patient is asymptomatic and free of complications, and the disease potentially reversible. Ultimately, the LiverScreen study will serve as a basis from which diagnostic pathways can be developed and adapted to the specific socio-economic and healthcare conditions in each country. This study is registered on (). The online version contains supplementary material available at 10.1186/s12889-022-13724-6.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Correction, LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

  • Graupera, Isabel|||0000-0001-9170-9784
  • Thiele, Maja
  • Ma, Ann T.|||0000-0002-9059-111X
  • Serra-Burriel, Miquel
  • Pich, Judit
  • Fabrellas, Núria|||0000-0001-6720-0291
  • Caballería, Llorenç|||0000-0002-7990-0719
  • de Knegt, Robert J.
  • Grgurevic, Ivica
  • Reichert, Mathias
  • Roulot, Dominique
  • Schattenberg, Jörn M.
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Angeli, Paolo|||0000-0002-1913-0716
  • Tsochatzis, Emmanuel A.
  • Guha, Indra Neil
  • Garcia-Retortillo, M.|||0000-0001-6783-7604
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Hernández, Rosario
  • Hoyo, Jordi
  • Fuentes, Matilde
  • Madir, Anita
  • Juanola, Adrià|||0000-0003-4832-5130
  • Soria, Anna|||0000-0001-5671-8343
  • Juan, Marta
  • Carol, Marta
  • Díaz, Alba|||0000-0002-0456-7085
  • Detlefsen, Sönke
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Pera, Guillem|||0000-0003-3188-7268
  • Fournier, Céline
  • Llorca, Anne
  • Newsome, Phillip N.
  • Manns, Michael|||0000-0002-4485-8856
  • de Koning, Harry J.
  • Serra-Burriel, Feliu
  • Cucchietti, Fernando|||0000-0002-9027-1263
  • Arslanow, Anita
  • Korenjak, Marko|||0000-0003-4024-677X
  • van Kleef, Laurens
  • Falcó, Josep Lluis
  • Kamath, P.S.|||0000-0002-7888-1165
  • Karlsen, Tom H.
  • Castera, Laurent
  • Lammert, Frank
  • Krag, Aleksander|||0000-0002-9598-4932
  • Ginès, Pere|||0000-0003-4657-4504